Learn due diligence best practices from leading global pharmaceutical professionals in this Q&A white paper on how to form productive biopharma partnerships.

This white paper discusses...

  • What large pharma expects when entering due diligence with a biopharma company
  • The importance of IP due diligence
  • The best ways to present and stage information that is disclosed to a potential partner
  • Common mistakes and how to avoid them 
  • How to recognize potential problems and address them early in the process
  • The best practices for the best long-term partnerships

If you are seeking to partner with another biopharmaceutical company, or desire to out- or in-license a drug, you will want to hear these perspectives. Request a copy.

the white paper